ACCESS TO ORPHAN DRUGS IN FRANCE - THE CASE OF SIKLOS FOR THE TREATMENT OF SICKLE CELL SYNDROME BEFORE THE COUNCIL OF STATE
Author(s)
Murteira S1, El Hammi E2, Kornfeld A3, Toumi M4
1Lundbeck Japan KK, Tokoyo, Japan, 2Evidenz, Tunis, Tunisia, 3Creativ-Ceutical, Paris, France, 4University of Marseille, Marseille, France
Background: Hydroxycarbamid is an antineoplastic molecule commercialized since 1968 in France under the name Hydrea®
Conference/Value in Health Info
2014-11, ISPOR Europe 2014, Amsterdam, The Netherlands
Value in Health, Vol. 17, No. 7 (November 2014)
Code
PHP295
Topic
Health Policy & Regulatory
Disease
Rare and Orphan Diseases, Systemic Disorders/Conditions